Syros Pharma and Global Blood Therapeutics shares were on the move on Wednesday after the companies announced a collaboration to develop and commercialize novel therapies for sickle cell disease and beta thalassemia.
Solid Biosciences shares jumped on Wednesday after the firm provided an update from its midstage study in Duchenne muscular dystrophy.
Adamas Pharma shares dropped sharply on Tuesday after the firm reported results from its late-stage multiple sclerosis study.
ImmunoGen shares jumped on Tuesday after the FDA advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval.
Proteostasis shares were absolutely crushed on Tuesday after the firm announced midstage data from its cystic fibrosis study. What comes next?
The influenza season officially runs from October to as late as May each year. Activity peaks around the end of the year and into January, which means that the U.S. is in its peak…
Prevail Therapeutics shares jumped early on Tuesday after the firm announced that the FDA has granted Orphan Drug designation for its dementia treatment.
Goldman Sachs believes that several health care companies can win, and it has three top picks for 2020 that may seem counterintuitive.
Sarepta shares jumped on Friday after the firm announced that the FDA has approved Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD) in certain patients.
Independent research firm Argus sees better than 25% potential upside for Bristol-Myers Squibb in the coming year.
The American Society of Hematology (ASH) hosted its 61st annual meeting and one of the biggest biotech events earlier this week in Orlando, Florida.
Puma Biotechnology shares made a handy gain early on Thursday after the company presented updated results from its Phase 2 Summit clinical trial of neratinib at the 2019 San Antonio Breast Cancer Symposium.
Correvio Pharma shares were crushed after the firm announced the FDA Cardiovascular and Renal Drugs Advisory Committee decision for its New Drug Application seeking approval for Brinavess. This could result in a sale of…
Proteostasis shares jumped on Wednesday after the firm announced positive, initial ex-vivo results of its proprietary cystic fibrosis transmembrane conductance regulator modulators, PTI-801, PTI-808 and PTI-428.
The November 29 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
